Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchitis Clear all
Completed Phase 2 Interventional

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

NCT00013702
View directory record Official record
Conditions
Hepatitis B, HIV Infection
Interventions
Adefovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

NCT02036970
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Respiratory Bronchiolitis Associated Interstitial Lung Disease, Desquamative Interstitial Pneumonia, Cryptogenic Organizing Pneumonia, Acute Interstitial Pneumonitis, Idiopathic Lymphoid Interstitial Pneumonia, Idiopathic Pleuroparenchymal Fibroelastosis
Interventions
Bardoxolone methyl, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 25, 2026, 5:42 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

NCT04959175
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI)
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 85 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 5:42 PM EDT
Active, not recruiting No phase listed Observational

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

NCT05250037
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Home spirometry, Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
8 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Ann Arbor, Michigan • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 25, 2026, 5:42 PM EDT
Enrolling by invitation No phase listed Observational

Shortwave Infrared Surgical Imaging Device Study

NCT07744425
View directory record Official record
Conditions
Cholecystitis, Cholecystitis, Chronic, Chronic Calculous Cholecystitis, Primary Hyperparathyroidism, Sigmoid Colon Diverticulitis, Multinodular Goiter, Thyroid and Parathyroid Surgery
Interventions
Observational study of SWIR imaging device in surgery
Device
Lead sponsor
Cision Vision, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Palo Alto, California • Evanston, Illinois • Glenview, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 25, 2026, 5:42 PM EDT
Terminated Phase 2 Interventional Results available

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

NCT01226420
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Alefacept
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 25, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo

NCT01049360
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium 400 μg / Formoterol 12 μg, Aclidinium 400 μg / Formoterol 6 μg, Aclidinium 400 μg, Formoterol 12 μg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Glendale, Arizona • Pheonix, Arizona • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 25, 2026, 5:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Implications of TNF

NCT00729131
View directory record Official record
Conditions
Bronchitis
Interventions
Etanercept inhibition of ozone-induced airway hyper-responsiveness.
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 25, 2026, 5:42 PM EDT
Withdrawn Phase 4 Interventional

Outpatient Registry Trial of Respiratory Tract Infections in Adults

NCT00245453
View directory record Official record
Conditions
Pneumonia, Bacterial, Bronchitis, Chronic
Interventions
azithromycin, telithromycin, Clarythromycin
Drug
Lead sponsor
CPL Associates
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Louisville, Kentucky • Slidell, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Oct 25, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

NCT01844765
View directory record Official record
Conditions
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
10
States / cities
Loma Linda, California • Palo Alto, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 25, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection

NCT01435044
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
42
States / cities
Montgomery, Alabama • Bakersfield, California • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 25, 2026, 5:42 PM EDT
Recruiting Phase 3 Interventional

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
30
States / cities
Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 5:42 PM EDT
Recruiting Not applicable Interventional

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

NCT07535008
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Interventions
Dental Cleaning, Dental Plaque sampling
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 5:42 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

NCT04583735
View directory record Official record
Conditions
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Interventions
TEPEZZA, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 25, 2026, 5:42 PM EDT
Recruiting No phase listed Observational

Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome

NCT04604522
View directory record Official record
Conditions
Bronchiolitis Obliterans
Interventions
Biospecimen Collection, Medical Chart Review
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 5:42 PM EDT
Not listed Phase 2 Interventional

Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

NCT01158105
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Bortezomib
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 25, 2026, 5:42 PM EDT
Recruiting Not applicable Interventional

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial

NCT05236062
View directory record Official record
Conditions
Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Interventions
Exercise, Attention control
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 25, 2026, 5:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease

NCT00371527
View directory record Official record
Conditions
Bronchitis
Interventions
ipratropium
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2008 · Synced Oct 25, 2026, 5:42 PM EDT
Terminated Phase 4 Interventional Results available

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

NCT02228382
View directory record Official record
Conditions
Previously Treated PH + CML
Interventions
Bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Deerfield Beach, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 25, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis

NCT00645086
View directory record Official record
Conditions
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).
Interventions
clarithromycin extended-release tablets, clarithromycin immediate-release tablets
Drug
Lead sponsor
Abbott
Industry
Eligibility
40 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
135
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hoover, Alabama + 122 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Oct 25, 2026, 5:42 PM EDT
Terminated Not applicable Interventional

Improving Hand Recovery With Neuromodulation in Tetraplegia

NCT03954496
View directory record Official record
Conditions
Spinal Cord Injuries, Tetraplegia, Unspecified, Incomplete, Chronic
Interventions
transcranial direct current stimulation, Intensive upper extremity motor training
Device · Behavioral
Lead sponsor
Sara Shahid Salles
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 25, 2026, 5:42 PM EDT
Active, not recruiting Not applicable Interventional

Respiratory Support and Treatment for Efficient and Cost-Effective Care

NCT05909566
View directory record Official record
Conditions
Bronchiolitis
Interventions
Clinical Decision Support (CDS), HHFNC Weaning
Other · Device
Lead sponsor
Christopher Horvat
Other
Eligibility
Up to 2 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 25, 2026, 5:42 PM EDT
Active, not recruiting Phase 3 Interventional

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
32
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 5:42 PM EDT
Active, not recruiting Not applicable Interventional

Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease

NCT06458127
View directory record Official record
Conditions
Chronic Graft-versus-host Disease, Chronic GVHD, cGVHD
Interventions
Tele-palliative care visit
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 25, 2026, 5:42 PM EDT